Straight talk with...Dalvir Gill

Abstract

In the pharmaceutical world, partnerships between two drugmakers are common, but rarely do more than a few companies—especially large ones—collaborate directly on the same project. So last September, when ten pharmaceutical giants announced the formation of a Philadelphia-based nonprofit called TransCelerate BioPharma as a vehicle for sharing resources, the industry took notice. The founding members include big names such as GlaxoSmithKline, Johnson & Johnson and Pfizer, all of whom joined with the aim of making clinical trials more efficient.

This year kicked off with an important milestone for TransCelerate: the appointment of its first chief executive, Dalvir Gill. An elected member of the UK's Royal Society of Medicine, Gill comes to TransCelerate after most recently serving as president of phase 2–4 drug development at PharmaNet-i3, an international contract research organization headquartered in Princeton, New Jersey. He spoke with Roxanne Khamsi about his vision of how pharmaceutical firms can work together to simplify the process of multisite trials without sacrificing the quality of the data they collect.